Core Viewpoint - The Gross Law Firm is notifying shareholders of Caribou Biosciences, Inc. regarding a class action lawsuit due to alleged misleading statements and financial risks associated with the company's product CB-010 [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from July 14, 2023, to July 16, 2024 [2]. - Allegations include that Caribou overstated the safety, efficacy, and durability of CB-010 compared to approved therapies, and failed to disclose significant risks regarding cash and liquidity [2]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by February 24, 2025, to potentially become lead plaintiffs [3]. - Registration allows shareholders to receive updates on the case through portfolio monitoring software [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

NEW YORK, Feb. 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the “Class Period”), of the important February 24, 2025 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

NEW YORK, Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=127841&from=4 CLASS PERIOD: Ju ...

NEW YORK, Feb. 4, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) and certain officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 24-cv- 09413 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 1 ...

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Caribou Biosciences, Inc. (NASDAQ: CRBU) securities between July 14, 2023 and July 16, 2024. Caribou is a clinical-stage biopharmaceutical company that purports to develop genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the U.S. and internationally.For more information, submit a form, email atto ...

NEW YORK, Feb. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=126272&from=4 CLASS PERIOD: Jul ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Caribou To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Caribou between July 14, 2023 and July 16, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 2, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP ...

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU).Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/caribou-biosciences-inc-loss-submission-form/?id=125752&from=4 CLASS PERIOD: Ju ...

NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou Biosciences, Inc." or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou Biosciences, Inc. investors who were adversely affected by alleged securities fraud between July 14, 2023 and July 16, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/ ...